Literature DB >> 30066045

Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone.

Yang Liu1,2, YuLan Sun3,2, Wei Wu1, AQian Li1, XianDa Yang4,2, Shuo Zhang1, Chuan Li1, QiuDong Su1,2, ShaoJian Cai5,2, DaPeng Sun6,2, HaiYang Hu7,2, Zhe Zhang8,2, XiuXu Yang8,2, Idrissa Kamara2,9, Sheku Koroma2,9, Gerald Bangura2,9, Alie Tia2,9, Abdul Kamara9, Matt Lebby9, Brima Kargbo9, Jiandong Li1, Shiwen Wang1, XiaoPing Dong1, YueLong Shu1, WenBo Xu1, George F Gao1,10, GuiZhen Wu1, DeXin Li1, William J Liu11,12, MiFang Liang13.   

Abstract

This study aimed to investigate the serological characteristics of Ebola virus (EBOV) infection during the late phase of the Ebola outbreak in Sierra Leone. In total, 877 blood samples from 694 suspected Ebola virus disease (EVD) cases assessed from March to December 2015, were analyzed via real-time reverse transcription polymerase chain reaction (RT-PCR) for viral RNA and enzyme-linked immunosorbent assay (ELISA) and Luminex to detect antibodies against EBOV. Viral load and EBOV-specific IgM/IgG titers displayed a declining trend during March to December 2015. Viral RNA load decreased rapidly at earlier stages after disease onset, while EBOV-specific IgM and IgG still persisted in 58.1% (18/31) and 93.5% (29/31) of the confirmed EVD patients and in 3.8% (25/663) and 17.8% (118/663) of the RNA-negative suspected patients in the later phase, respectively. Dynamic analysis of longitudinally collected samples from eight EVD patients revealed typically reversed trends of declining viral load and increasing IgM and/or IgG titers in response to the EBOV infection. The present results indicate that certain populations of Sierra Leone developed immunity to an EBOV infection in the late phase of the outbreak, providing novel insights into the risk assessment of EBOV infections among human populations.

Entities:  

Keywords:  Ebola virus (EBOV); IgG; IgM; Late phase; Serologic investigation

Mesh:

Substances:

Year:  2018        PMID: 30066045      PMCID: PMC6178096          DOI: 10.1007/s12250-018-0044-z

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  29 in total

1.  Detection of Ebola viral antigen by enzyme-linked immunosorbent assay using a novel monoclonal antibody to nucleoprotein.

Authors:  M Niikura; T Ikegami; M Saijo; I Kurane; M E Miranda; S Morikawa
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

3.  ELISA for the detection of antibodies to Ebola viruses.

Authors:  T G Ksiazek; C P West; P E Rollin; P B Jahrling; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

4.  New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors.

Authors:  Mamadou S Sow; Jean-François Etard; Sylvain Baize; N'Fally Magassouba; Ousmane Faye; Philippe Msellati; Abdoulaye Touré; Ibrahima Savane; Moumié Barry; Eric Delaporte
Journal:  J Infect Dis       Date:  2016-05-03       Impact factor: 5.226

5.  [Research of Human-mouse Chimeric Antibodies Against Ebola Virus Nucleoprotein].

Authors:  Rongping Zhou; Lina Sun; Yang Liu; Wei Wu; Chuan Li; Mifang Liang; Peihong Qiu
Journal:  Bing Du Xue Bao       Date:  2016-01

6.  Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report.

Authors:  Gibrilla F Deen; Nathalie Broutet; Wenbo Xu; Barbara Knust; Foday R Sesay; Suzanna L R McDonald; Elizabeth Ervin; Jaclyn E Marrinan; Philippe Gaillard; Ndema Habib; Hongtu Liu; William Liu; Anna E Thorson; Francis Yamba; Thomas A Massaquoi; Faustin James; Archchun Ariyarajah; Christine Ross; Kyle Bernstein; Antoine Coursier; John Klena; Marylin Carino; Alie H Wurie; Yong Zhang; Marion S Dumbuya; Neetu Abad; Baimba Idriss; Teodora Wi; Sarah D Bennett; Tina Davies; Faiqa K Ebrahim; Elissa Meites; Dhamari Naidoo; Samuel J Smith; Patricia Ongpin; Tasneem Malik; Anshu Banerjee; Bobbie R Erickson; Yongjian Liu; Yang Liu; Ke Xu; Aaron Brault; Kara N Durski; Jörn Winter; Tara Sealy; Stuart T Nichol; Margaret Lamunu; James Bangura; Sihem Landoulsi; Amara Jambai; Oliver Morgan; Guizhen Wu; Mifang Liang; Qiudong Su; Yu Lan; Yanzhe Hao; Pierre Formenty; Ute Ströher; Foday Sahr
Journal:  N Engl J Med       Date:  2015-10-14       Impact factor: 91.245

7.  Comprehensive multiplex one-step real-time TaqMan qRT-PCR assays for detection and quantification of hemorrhagic fever viruses.

Authors:  Zheng Pang; Aqian Li; Jiandong Li; Jing Qu; Chengcheng He; Shuo Zhang; Chuan Li; Quanfu Zhang; Mifang Liang; Dexin Li
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

8.  Ebola Virus Outbreak Investigation, Sierra Leone, September 28-November 11, 2014.

Authors:  Hui-Jun Lu; Jun Qian; David Kargbo; Xiao-Guang Zhang; Fan Yang; Yi Hu; Yang Sun; Yu-Xi Cao; Yong-Qiang Deng; Hao-Xiang Su; Foday Dafae; Yu Sun; Cheng-Yu Wang; Wei-Min Nie; Chang-Qing Bai; Zhi-Ping Xia; Kun Liu; Brima Kargbo; George F Gao; Jia-Fu Jiang
Journal:  Emerg Infect Dis       Date:  2015-11       Impact factor: 6.883

9.  Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013-2016.

Authors:  Tini Garske; Anne Cori; Archchun Ariyarajah; Isobel M Blake; Ilaria Dorigatti; Tim Eckmanns; Christophe Fraser; Wes Hinsley; Thibaut Jombart; Harriet L Mills; Gemma Nedjati-Gilani; Emily Newton; Pierre Nouvellet; Devin Perkins; Steven Riley; Dirk Schumacher; Anita Shah; Maria D Van Kerkhove; Christopher Dye; Neil M Ferguson; Christl A Donnelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-05-26       Impact factor: 6.237

10.  Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus.

Authors:  Andreas Lucht; Roland Grunow; Christian Otterbein; Peggy Möller; Heinz Feldmann; Stephan Becker
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 4.148

View more
  5 in total

1.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

2.  Evaluation of Diagnostic Performance of Three Indirect Enzyme-Linked Immunosorbent Assays for the Detection of IgG Antibodies to Ebola Virus in Human Sera.

Authors:  Janusz T Paweska; Naazneen Moolla; Nadia Storm; Veerle Msimang; Ousman Conteh; Jacqueline Weyer; Petrus Jansen van Vuren
Journal:  Viruses       Date:  2019-07-24       Impact factor: 5.048

3.  Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study.

Authors:  William J Liu; Foday R Sesay; Antoine Coursier; Barbara Knust; Jaclyn E Marrinan; Shannon Whitmer; Suzanna L R McDonald; Philippe Gaillard; Yang Liu; Qiudong Su; Yong Zhang; Ian Crozier; Archchun Ariyarajah; Marylin Carino; Thomas Massaquoi; Nathalie Broutet; Wenbo Xu; Guizhen Wu; Ute Ströher; George F Gao; Pierre Formenty; Foday Sahr; Gibrilla F Deen
Journal:  Open Forum Infect Dis       Date:  2019-02-26       Impact factor: 3.835

4.  Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Authors:  Jack Mellors; Tom Tipton; Sarah Katharina Fehling; Joseph Akoi Bore; Fara Raymond Koundouno; Yper Hall; Jacob Hudson; Frances Alexander; Stephanie Longet; Stephen Taylor; Andrew Gorringe; N'Faly Magassouba; Mandy Kader Konde; Julian Hiscox; Thomas Strecker; Miles Carroll
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

5.  Comparative performance study of three Ebola rapid diagnostic tests in Guinea.

Authors:  Zelda Moran; William Rodriguez; Doré Ahmadou; Barré Soropogui; N' Faly Magassouba; Cassandra Kelly-Cirino; Yanis Ben Amor
Journal:  BMC Infect Dis       Date:  2020-09-15       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.